5-Amino-1MQ 50mg — Research Protocol Reference

5-Amino-1MQ is administered via subcutaneous injection once daily throughout the active cycle.

Morning fasted dosing is strongly preferred, NNMT inhibition amplifies fat oxidation, and administering in a fasted low-insulin state maximises the lipolytic environment at the time of peak compound activity. The plasma half-life of approximately 3.8–6.9 hours means once-daily dosing provides sustained NNMT inhibition across the metabolically active morning window.

Do not use 5-Amino-1MQ if you are pregnant or breastfeeding, have cardiovascular disease, severe organ dysfunction, or a history of eating disorders. Monitor energy levels and appetite across the first two weeks, mild stimulatory effects are expected at therapeutic doses and typically normalise as tolerance establishes.

5-Amino-1MQ is a selective NNMT inhibitor that restores NAD+ availability in adipocytes, shifts fat cells from lipid storage to fat oxidation, and raises basal metabolic rate through mitochondrial activation. Preclinical research using SC administration documented significant body fat reductions and reversal of diet-induced obesity in animal models. The 2.5mg intro dose reflects the conservative titration approach used in clinic-supervised protocols to establish individual energy and metabolic response before advancing to the full 5mg maintenance dose. The 4-week rest period prevents NNMT receptor adaptation and maintains compound sensitivity across repeated cycles. At 3.5mL BAC, concentration is 14,286mcg/mL, all draws are approximate.

In biohacking forums, 5-Amino-1MQ at 2.5–5mg once daily fasted in the morning is the most commonly reported pattern, often stacked with AOD-9604 or other metabolic peptides for improved fat loss synergy. Twice-daily dosing at 2.5mg AM/PM is noted by some users seeking more sustained NNMT inhibition across the day given the compound's half-life. These are community-derived patterns, not clinical.

5-Amino-1MQ is injected subcutaneously once daily in the morning. Fasted state at the time of injection is the most important timing variable.

• Morning fasted, before food or coffee: Insulin suppresses lipolysis directly. Injecting in a fasted low-insulin state means NNMT inhibition activates fat oxidation in adipocytes at the moment they are most metabolically receptive. Eating within 1–2 hours post-injection blunts this window.
• Consistent daily timing: NNMT inhibition is cumulative across the cycle. Irregular dosing timing disrupts the steady-state inhibition that drives sustained fat oxidation improvements. Hold the same morning window within 30 minutes each day.
• Inject slowly: A mild stinging sensation at the injection site is a documented characteristic of the quinolinium structure, slow, steady injection pressure significantly reduces discomfort. Do not rush the draw.
• Rotate injection sites every session: Abdomen and outer thighs. With once-daily dosing across a 12-week cycle, consistent rotation prevents local tissue irritation and lipohypertrophy.
• Pair with a training session or fasted cardio where possible: Exercise and NNMT inhibition act on overlapping fat oxidation pathways. Combining morning fasted training with the daily injection maximises the lipolytic output of both.

• Fasted morning dosing is not optional for optimal effect: The entire mechanism of 5-Amino-1MQ depends on shifting adipocytes toward fat oxidation, an effect that is substantially blunted when insulin is elevated. Fasted administration is the single most important protocol variable.
• Mild stinging at injection site is expected: The quinolinium structure of 5-Amino-1MQ produces a characteristic mild sting on injection. This is not a sign of contamination or incorrect reconstitution, inject slowly to minimise it and rotate sites consistently.
• Effects build across the cycle: NNMT inhibition drives metabolic changes at the cellular level, fat loss results are cumulative and typically become measurable at weeks 4–6. Do not adjust dose based on early cycle response.
• Stack considerations: 5-Amino-1MQ is commonly paired with AOD-9604 for complementary fat loss mechanisms, AOD-9604 targets lipolysis through GH fragment activity while 5-Amino-1MQ targets NNMT inhibition and NAD+ restoration. Both can be administered in the same morning fasted window from separate syringes.
• Discard at 28–30 days post-reconstitution. At 5mg/day, a 50mg vial provides approximately 10 days of material, plan vial supply for the full cycle accordingly.

Taking too much 5-Amino-1MQ can increase side effects. Signs your dose may be too high:

• Overstimulation or restlessness: The most commonly reported above-range sign. Elevated NAD+ and mitochondrial activation can produce a stimulatory effect that becomes uncomfortable at above-threshold doses. Reduce to 2.5mg and hold for one week before reassessing.
• Nausea: Reported at higher doses, particularly when dosed in a fed state. Confirm fasted timing before reducing dose. If nausea persists in a fasted state, reduce to 2.5mg.
• Injection site irritation beyond 24 hours: Persistent redness or swelling beyond one day. Reduce dose volume, inject more slowly, and rotate sites more consistently.
• Sleep disruption: Morning dosing is specifically recommended to avoid the stimulatory effects of NAD+ elevation interfering with sleep onset. If sleep is disrupted, confirm dosing is occurring before 9 AM and reduce to 2.5mg if it persists.

If any of these occur, reduce to 2.5mg once daily and hold for one week before attempting to advance again.

A dose may be too low if expected effects are absent after consistent use. Common indicators:

• No change in energy levels or metabolic rate after 3–4 weeks at 5mg: Confirm fasted timing at every injection before adjusting. If timing is confirmed correct and no effect is present after 4 weeks, the compound may require stacking with a complementary metabolic peptide for measurable results at this dose.
• No visible change in body composition after 6 weeks with consistent diet and training: 5-Amino-1MQ works through cellular metabolic shifts, results require a caloric context to be visible. Confirm diet and training are consistent before attributing absence of results to dosing.
• No injection site sting at any dose: The mild stinging characteristic of this compound at therapeutic doses is entirely absent. This may indicate dissolution issues, confirm the vial is fully dissolved before drawing and that the reconstituted solution has not been frozen.

If these indicators persist after a full 6-week maintenance phase with confirmed fasted timing and correct technique, advancing to twice-daily dosing at 2.5mg AM/PM is within the documented community range before reassessing.

⚠️ This is for informational purposes only. For medical advice or diagnosis, consult a professional. ⚠️